BPG is committed to discovery and dissemination of knowledge
Retrospective Study
©The Author(s) 2025.
World J Gastrointest Surg. Nov 27, 2025; 17(11): 110262
Published online Nov 27, 2025. doi: 10.4240/wjgs.v17.i11.110262
Table 5 Clinical efficacy indicators and subgroup analysis, mean ± SD/n (%)
Assessment indicators
Acupuncture group (n = 120)
Control group (n = 120)
Statistical value
P value
Symptom severity
    PONV VAS score, points2.7 ± 1.44.5 ± 1.8t = 8.456< 0.01
    Relative improvement40.0
    Mild symptoms (VAS 1-3)92 (76.5)42 (35.1)χ² = 41.832< 0.01
Time effect analysis
    Time to first PONV onset, hours8.4 ± 2.14.2 ± 1.5t = 17.429< 0.01
    Symptom-free period extension (hours)4.2
    Extension effect100.0
Symptom-free patientsχ² = 37.842< 0.01
    Symptom-free patients within 6 hours81 (67.6)34 (28.1)
Symptom duration analysis
    Average duration, hours2.8 ± 1.64.7 ± 2.3t = 7.321< 0.01
    Reduction rate40.4
Medication usage
    Rescue antiemetic medication usage22 (18.3)43 (35.8)χ² = 9.524< 0.01
Gender subgroup
    Female PONV overall incidence70/162 (43.2)70/162 (43.2)χ² = 6.892< 0.05
    Male PONV overall incidence21/78 (26.9)21/78 (26.9)χ² = 6.892< 0.05
    Efficacy by genderSignificant for both gendersSignificant for both genders< 0.05
Age stratification
    ≤ 45 years group reduction rate23.5F = 4.832< 0.05
    > 45 years group reduction rate16.8F = 4.832< 0.05
    Inter-age group differenceBetter in ≤ 45 years groupF = 4.832< 0.05
High-risk patients
    High-risk patients (Apfel score ≥ 3)47 patients45 patients
    PONV incidence in high-risk patients17/47 (36.2)28/45 (62.2)χ² = 6.542< 0.01
    Risk reduction in high-risk patients41.8
Safety profile
    Total mild adverse reactions7 (5.8)0 (0)
    Mild pain at acupuncture points4 (3.3)0 (0)
    Minor local bleeding2 (1.7)0 (0)
    Transient dizziness1 (0.8)0 (0)
ResolutionAll self-resolved
Serious adverse reactionsNone reportedNone reported


Write to the Help Desk